Data availability 157
The datasets generated during and/or analyzed during the current study are available 158 from the corresponding author on reasonable request.
RESULTS 161
Study Population 162 98 potential participants were screened for entry into the study. Of these, 64 were 163 ineligible (24 started TB therapy before they could be approached for consent, 17 were 164 HIV negative, 9 were transferred in to the facility already on TB treatment, 5 were 165 already enrolled in another study, 5 were prisoners, 2 had been started on antiretroviral 166 therapy in the 12 weeks before admission, and 2 were unable to provide informed 167 consent due to altered mental state). 36 individuals were approached for enrollment and 168 20 consented to participate. None of the participants withdrew consent at a later date 169 and all were followed for at least 16 weeks or until death. 170
Most participants were male (n=13), with median age of 41 years (inter-quartile range 171 (IQR) 33 to 48y) ( Table 1) We conducted a study that prospectively followed a cohort of 20 participants with HIV 218 and MDR-TB co-infection for the first 4 months of their therapy and found that 219 individuals who had higher CRP concentrations at the start of a time interval had a 220 significantly increased hazard of dying. The relative decrease in CRP in survivors was 221 similar to that seen in other work by our group in people with HIV and drug-sensitive TB 222 (manuscript in preparation) with a failure to reduce CRP by 44% at week 2 the most 223 sensitive cutoff of predicting death. Baseline fibrinogen was also significantly higher in 224 those that died. 225
Older age was a significant baseline predictor of death, a finding which has been 226 reported by others in South Africa 
